Stem Cell Transplantation for Hurler

Mucopolysaccharidosis I Clinical Trial

Official title:

Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00176917
• Other study ID #: UMN-MT1999-07
• Secondary ID: 0104M93821
• Status: Completed
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: December 3, 2017
• Start date: May 1999
• Est. completion date: May 2010

Study information

• Verified date: December 2017
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome, Maroteaux Lamy syndrome, Mannosidosis, or I-cell disease.

Description:

Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman line four times daily for 4 days, Cyclophosphamide intravenously via the Hickman line once a day for 4 days, and Anti-Thymocyte Globulin IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to subjects to help the new marrow "take" and grow.

On the day of transplantation, the donor's hematopoietic cells will be transfused via central venous catheter.

After hematopoietic cell transplant, subjects will then receive two drugs, cyclosporin and either methylprednisolone or Mycophenolate Mofetil (MMF). Cyclosporin and methylprednisolone or MMF are given to help prevent the complication of graft-versus-host disease and to decrease the chance that the new donor cells will be rejected.

Other known NCT identifiers

• NCT00005899

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: May 2010
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with Mucopolysaccharidosis, type I (e.g., Hurler syndrome), Maroteaux-Lamy syndrome (MPS VI), Alpha Mannosidosis, or mucolipidosis type II (I-cell disease) who have an HLA-identical or mismatched (at 1 antigen) related marrow, PBSC, or cord blood donor.

• Patients with Mucopolysaccharidosis, type I, Maroteaux-Lamy syndrome (MPS VI), Alpha Mannosidosis, or mucolipidosis type II (I-cell disease) who have an HLA-identical or HLA-1 antigen mismatched unrelated marrow, PBSC, or HLA-0-2 antigen mismatched umbilical cord blood donor.

• Patients with MPS type I, Maroteaux Lamy Syndrome (MPS VI), or mucolipidosis type II (I-cell disease) will have a mental developmental index within two standard deviations of the normal mean, as best as can be determined using Bayley scales of infant development or other standardized testing, recognizing that these may be affected by speech and/or hearing impairment.

• Adequate organ function:

• Cardiac: ejection fraction >40%; no decompensated congestive heart failure or uncontrolled arrhythmia

• Renal: serum creatinine <2.0 mg/dl

• Hepatic: total bilirubin <3x Upper limits of normal transaminases < 5.0 x Upper limits of normal

• Signed consent.

Exclusion Criteria:

• Presence of major organ dysfunction (see above)

• Pregnancy

• Evidence of HIV infection or known HIV positive serology

• Patients or parents are psychologically incapable of undergoing BMT with associated strict isolation or documented history of medical non-compliance

• Patients >50 kg may be at risk for having cell doses below the goal of = 10 x 106 CD 34 cells/kg and therefore will not be eligible to receive unrelated PBSCs.

Related Conditions & MeSH terms

• alpha-Mannosidosis
• Mannosidosis
• Mucolipidosis Type II (I-cell Disease)
• Mucopolysaccharidoses
• Mucopolysaccharidosis I
• Mucopolysaccharidosis VI

Intervention

Procedure:
• Stem Cell Transplant
The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).

Drug:
• Busulfan, Cyclophosphamide, ATG
Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow "take" and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.

Locations

Country	Name	City	State
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Percentage of Donor Cells in Study Population (Chimerism).	Donor-derived engraftment determined by restriction fragment length polymorphism (RFLP).	at 21 days, 42 days, 60 days, 100 days, 6 months, and 1 year
Secondary	Number of Patients Surviving on Study	Number of patients surviving (alive) at specified timepoints.	at 100 days, 1 year, and 3 years post transplant
Secondary	Number of Patients Who Failed Engraftment.	Toxicity (undesireable effect) of hematologic donor cell engraftment is determined by failure to engraft at Day 42.	Day 42 Post Transplant
Secondary	Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD).	Toxicity (undesireable effect) of this stem cell transplant preparative regimen due to acute graft-versus-host disease.	Day 100 Post Transplant